Article Text

Download PDFPDF

Authors’ reply
  1. J W Wilson1,
  2. R M du Bois2,
  3. T E King3
  1. 1
    Department of Respiratory Medicine, The Alfred Hospital, Prahran, Australia
  2. 2
    Royal Brompton Hospital, London, UK
  3. 3
    San Francisco General Hospital, San Francisco, California, USA
  1. Dr J W Wilson, Department of Respiratory Medicine, The Alfred Hospital, Prahran 3181, Australia; john.wilson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We are most grateful for the response to our call for an international registry for idiopathic pulmonary fibrosis (IPF) from the European IPF Network collaborators.1 This most timely registry should be the forerunner of similar disease-specific approaches to problem-solving in health care. The concept of biomaterial collection in conjunction with clinical data should encourage participation from scientists with an ability to contribute to knowledge of the pathogenesis of IPF. We feel this most positive beginning should be a stimulus to other groups, particularly in North America and the Asia-Pacific region, to follow this European initiative.


View Abstract


  • Competing interests: None.

Linked Articles